Eledon Pharmaceuticals to Present Phase 2 Kidney Transplant Data at ASN Kidney Week 2026
Event summary
- Eledon Pharmaceuticals will present oral data from the Phase 2 BESTOW trial at ASN Kidney Week 2026 on October 23.
- The presentation will focus on patient-reported outcomes comparing tegoprubart to tacrolimus in kidney transplant recipients.
- Andrew B. Adams, M.D., Ph.D., from the University of Minnesota Medical School, will deliver the presentation.
- The trial evaluates tegoprubart, an anti-CD40L antibody, for preventing rejection in kidney transplantation.
The big picture
Eledon's presentation at ASN Kidney Week 2026 comes as the biotech industry increasingly focuses on targeted immunomodulation for organ transplantation. The Phase 2 data could validate tegoprubart's potential as a safer alternative to existing immunosuppressants, addressing a critical unmet need in kidney transplant care. Success here may also open doors for Eledon in other transplant and autoimmune indications.
What we're watching
- Clinical Efficacy
- How the patient-reported outcomes from the BESTOW trial will position tegoprubart against existing standards like tacrolimus.
- Regulatory Pathway
- Whether positive data could accelerate tegoprubart's development timeline for kidney transplantation and other indications.
- Market Differentiation
- The pace at which Eledon can establish tegoprubart as a non-lymphocyte-depleting alternative in the transplant space.
Related topics